Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Berinert for Refractory Antibody Mediated Rejection in Kidney Transplant
NCT02936479Phase 2Completed
- Sponsor
- NYU Langone Health
- Start
- Oct 2016
- Primary completion
- Oct 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of c1-esterase inhibitor in antibody mediated rejection (AMR), sponsored by NYU Langone Health. Primary endpoint: Renal Allograft Survival Measured by Severe and Refractory Antibody Mediated Renal (AMR) at 24 months. Started Oct 2016; status: completed.
02
Drugs
c1-esterase inhibitor
03
Conditions
antibody mediated rejection (AMR)
Beyond the preview
Go deeper on NCT02936479.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02936479.